Abigail L Miller - JoVE Visualize

Showing results (1-10 of 6) with videos related to

Pageof 1

Sort By:

Nature|July 11, 2003

Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entryJulien Sage, Abigail L Miller, Pedro A Pérez-Mancera, et al.

Advances in Cancer Research|July 15, 2009

Ras signaling and therapiesAmy Young, Jesse Lyons, Abigail L Miller, et al.

Cancer Research|March 20, 2023

DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon CancerAbigail L Miller, Naiara Perurena, Alycia Gardner, et al.

ACS Macro Letters|June 2, 2022

Nanoparticle-Encapsulated Hollow Porous Polymeric Nanosphere Frameworks as Highly Active and Tunable Size-Selective CatalystsYang Xu, Yuxing Yao, Haitao Yu, et al.

The Journal of Clinical Investigation|May 10, 2016

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancersRebecca Lock, Rachel Ingraham, Ophélia Maertens, et al.

Cell Reports. Medicine|April 8, 2023

USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilitiesNaiara Perurena, Rebecca Lock, Rachel A Davis, et al.

Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:

Pageof 1

Nature|July 11, 2003

Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entryJulien Sage, Abigail L Miller, Pedro A Pérez-Mancera, et al.

Advances in Cancer Research|July 15, 2009

Ras signaling and therapiesAmy Young, Jesse Lyons, Abigail L Miller, et al.

Cancer Research|March 20, 2023

DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon CancerAbigail L Miller, Naiara Perurena, Alycia Gardner, et al.

ACS Macro Letters|June 2, 2022

Nanoparticle-Encapsulated Hollow Porous Polymeric Nanosphere Frameworks as Highly Active and Tunable Size-Selective CatalystsYang Xu, Yuxing Yao, Haitao Yu, et al.

The Journal of Clinical Investigation|May 10, 2016

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancersRebecca Lock, Rachel Ingraham, Ophélia Maertens, et al.

Cell Reports. Medicine|April 8, 2023

USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilitiesNaiara Perurena, Rebecca Lock, Rachel A Davis, et al.

Pageof 1